The American College of Rheumatology released guiding principles for the allocation, use, and management of hydroxychloroquine during the COVID-19 pandemic.
In the US, individuals with underlying health conditions have an increased risk for severe coronavirus disease 2019.
The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”
Researchers investigated whether the influenza vaccine was effective in preventing respiratory morbidity, mortality, and all-cause mortality in patients with autoimmune rheumatic diseases.
The FDA has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test, a molecular point-of-care test that delivers results within minutes.
Researchers described the efficacy of tofacitinib in reducing pain in patients with inflammatory rheumatic and musculoskeletal diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The National Institutes of Health has launched a new website with educational resources for workers at risk for exposure to COVID-19.
Combined interventions of quarantining infected individuals and their family members can reduce the number of SARS-CoV-2 infections.
Researchers explored the incidence rates of hepatobiliary events in the first 6 months of routine treatment with the biosimilar etanercept or an originator drug in inflammatory joint disease.
Italy’s health care system is highly regarded, having more hospital beds per capita than the United States.
In this interview, Jane E Salmon, MD, provides insight into the risk for COVID-19 in pregnant women with rheumatic diseases.
Strong demand for medications that show promise as treatments for COVID-19 have led to shortages of those drugs in the United States.
The serial interval of COVID-19, defined as the time between a primary case and secondary case developing symptoms, is 3.96 days.
Experts provided recommendations on contraception, assisted reproductive technologies, fertility preservation, menopausal hormone replacement therapy, pregnancy, and medication use in patients with rheumatic and musculoskeletal diseases.
The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).